Lonsurf (trifluridine/tipiracil) / Otsuka 
Welcome,         Profile    Billing    Logout  
 6 Diseases   125 Trials   125 Trials   2571 News 


«12...2021222324252627282930...3334»
  • ||||||||||  Review, Journal:  Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer. (Pubmed Central) -  Sep 18, 2020   
    Regorafenib, TAS-102 and SIRT using Y-90 resin microspheres are more effective than BSC in third-line treatment of mCRC; however, study heterogeneity made comparisons between active treatments challenging. SIRT is a viable treatment for third-line mCRC and its favorable AE profile should be considered in the therapeutic decision-making process.
  • ||||||||||  Review, Journal:  Cellular Mechanisms Accounting for the Refractoriness of Colorectal Carcinoma to Pharmacological Treatment. (Pubmed Central) -  Sep 18, 2020   
    In the present review, we have inventoried the genes involved in the lack of CRC response to pharmacological treatment, classifying them into seven groups (from MOC-1 to MOC-7) according to functional criteria to identify cancer cell weaknesses. This classification will be useful to pave the way for developing sensitizing tools consisting of (i) new agents to be co-administered with the active drug; (ii) pharmacological approaches, such as drug encapsulation (e.g., into labeled liposomes or exosomes); (iii) gene therapy interventions aimed at restoring the impaired function of some proteins (e.g., uptake transporters and tumor suppressors) or abolishing that of others (such as export pumps and oncogenes).
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka, Vectibix (panitumumab) / Amgen, Stivarga (regorafenib) / Bayer
    Trial primary completion date:  PULSE: Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer (clinicaltrials.gov) -  Sep 16, 2020   
    P2,  N=120, Recruiting, 
    This classification will be useful to pave the way for developing sensitizing tools consisting of (i) new agents to be co-administered with the active drug; (ii) pharmacological approaches, such as drug encapsulation (e.g., into labeled liposomes or exosomes); (iii) gene therapy interventions aimed at restoring the impaired function of some proteins (e.g., uptake transporters and tumor suppressors) or abolishing that of others (such as export pumps and oncogenes). Trial primary completion date: Aug 2021 --> Dec 2022
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma (clinicaltrials.gov) -  Sep 15, 2020   
    P1,  N=20, Recruiting, 
    Trial primary completion date: Aug 2021 --> Dec 2022 Trial completion date: Jun 2022 --> Sep 2022 | Trial primary completion date: Jul 2020 --> Dec 2020
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TAS / 102
    Review, Journal:  Metastatic Colorectal Carcinoma after Second Progression and the Role of Trifluridine-Tipiracil (TAS-102) in Switzerland. (Pubmed Central) -  Sep 9, 2020   
    However, FTD/TPI as well as regorafenib are recommended by the current ESMO, German S3, and National Comprehensive Cancer Network (NCCN) guidelines in the same situation, thus offering physicians a number of alternatives for the treatment of mCRC patients after the second progression. Key Message: This narrative review summarizes published data and their impact for FTD/TPI as well for regorafenib and rechallenge chemotherapy in clinical practice settings of refractory situations of colorectal cancer.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, gemcitabine / Generic mfg.
    Journal:  Current treatment landscape and emerging therapies for pancreatic cancer. (Pubmed Central) -  Aug 30, 2020   
    Currently, inhibitors of immune tolerance and immune checkpoint inhibitors; PARP inhibitors; novel cytotoxic chemotherapies, such as trifluridine/tipiracil; and modifiers of the tumor microenvironment, such as pegylated hyaluronidase, are in clinical trials for the treatment of pancreatic cancer. This activity will review the current treatment landscape and preview emerging therapies for the treatment of advanced pancreatic cancer.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, irinotecan / Generic mfg.
    Clinical, Review, Journal:  Clinical Evaluation of the Safety and Efficacy of Trifluridine/Tipiracil in the Treatment of Advanced Gastric/Gastroesophageal Junction Adenocarcinoma: Evidence to Date. (Pubmed Central) -  Aug 18, 2020   
    Trifluridine/tipiracil or TAS-102 (Taiho Oncology, Lonsurf, Princeton, NJ, USA) is a combination tablet of trifluridine, a thymidine-based nucleoside analog, and tipiracil, a thymidine phosphorylase inhibitor, in a 1:0.5 molar ratio...Recently, the U S Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have granted approval of trifluridine/tipiracil for treatment of metastatic gastric and gastroesophageal junction adenocarcinoma in patients following at least two lines of chemotherapy including fluoropyrimidine and platinum chemotherapy agents, as well as taxanes or irinotecan...Treatment with trifluridine/tipiracil not only did not impair quality of life but also tended to reduce the risk of deterioration of quality of life. The results of these studies along with the subsequent FDA and EMA approval have generated an important breakthrough in regard to treatment options for patients with refractory metastatic gastric or gastroesophageal junction adenocarcinoma.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TAS / 102, Stivarga (regorafenib) / Bayer
    Review, Journal:  Refractory Metastatic Colorectal Cancer: Current Challenges and Future Prospects. (Pubmed Central) -  Aug 9, 2020   
    Rare molecular subtypes of mCRC are increasingly being identified, including Her2-positive disease, NTRK fusions and others. Clinical trials exploring the efficacy of immunomodulatory and precision agents are plentiful and will hopefully yield clinically meaningful results that can be rapidly translated into routine care.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka
    Trial completion date, Trial termination, Trial primary completion date, Metastases:  TAS-102 (Lonsurf) in Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Post First Line Chemotherapy (UF-STO-PANC-003) (clinicaltrials.gov) -  Aug 8, 2020   
    P2,  N=7, Terminated, 
    Clinical trials exploring the efficacy of immunomodulatory and precision agents are plentiful and will hopefully yield clinically meaningful results that can be rapidly translated into routine care. Trial completion date: Nov 2021 --> Jul 2020 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2020 --> Jan 2020; insufficient time to accrue sufficient subjects before end of funding
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TAS / 102
    Clinical, Journal:  Safety Report of TAS-102 in a Patient With Reduced DPD Activity. (Pubmed Central) -  Jul 25, 2020   
    Given its tolerability and the observed trend in survival benefit compared with regorafenib 160, dose escalation strategy of regorafenib (80+) may be the preferred option in this setting. No abstract available